



NDA 20955/S017

## SUPPLEMENT APPROVAL

Sanofi-Aventis U. S. LLC  
Attention: Ying Zheng  
Senior Associate, Regulatory Affairs  
55 Corporate Drive  
Mail Stop: 55C-205 A  
Bridgewater, NJ 08807

Dear Ms. Zheng:

Please refer to your supplemental new drug application (sNDA) dated and received September 12, 2020, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Ferrlecit (sodium ferric gluconate complex in sucrose injection) for intravenous use.

This “Changes Being Effected” supplemental new drug application provides for revisions to sections 4 (Contraindications), 5.4 (Risk of Serious Adverse Reactions in Infants Due to Benzyl Alcohol), 6.2 (Postmarketing Experience), 8.1 (Pregnancy), 8.4 (Pediatric Use), 11 (Description) and 16 (How Supplied/Storage and Handling) of the package insert.

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling text for the Prescribing Information with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Charlene Wheeler, Acting Chief, Project Management Staff at 301-796-1141.

Sincerely,

*{See appended electronic signature page}*

Albert Deisseroth, MD, PhD  
Supervisory Associate Director  
Division of Nonmalignant Hematology  
Office of Cardiology, Hematology,  
Endocrinology and Nephrology  
Center for Drug Evaluation and Research

ENCLOSURE(S): Prescribing Information

---

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

ALBERT B DEISSEROTH  
03/31/2020 03:01:35 PM